Brain and Cognition Discovery Foundation - BCDF

Home
Canada
Toronto, ON
Brain and Cognition Discovery Foundation - BCDF

Furthermore, we aim towards putting affected individuals back on to the normal trajectory with cure of illness as an overarching objective.

The Brain and Cognition Discovery Foundation (BCDF) is a registered non-profit organization based in Toronto, Canada led by Dr. Roger McIntyre, MD, FRCPC.

*NEW NEUROIMAGING MDD STUDY OPEN*
Contact us at [email protected] The BCDF is particularly interested in the development of novel innovative strategies that are capable of augmenting best practices in today's healthcare ecosystem. The BC

DF actively also provides medical education/knowledge transfer with an overarching aim to narrow the implementation gap between medical knowledge and what is implemented at the point-of-care for persons with mental disorders. If you are interested in participating in the long COVID study, please email [email protected], or call 647-450-8045.

10/31/2025

We’re excited to share that our new research study is now recruiting for adults experiencing depression!

This study uses brain imaging to see how a new rapid-acting oral antidepressant, called Auvelity (a combination of dextromethorphan and bupropion), may affect brain activity. By looking at how the brain responds, researchers hope to learn more about how antidepressants work in the brain.

Auvelity has been approved by the U.S. FDA since August 2022, and this is the first time it will be available in Canada through a research study!

This is an open-label study, meaning there is no placebo group. This means that everyone who qualifies and takes part may receive the study medication. Participants will be compensated for their time.

If you or someone you know is living with depression, you may be eligible to join.
📩 Contact our team at [email protected] to learn more!

01/27/2025

The BCDF is recruiting participants for KOASTAL-2, a clinical study that is taking place in Toronto and Mississauga. This study will be evaluating the effects of a once-daily investigational treatment called Navacaprant on depressive symptoms and anhedonia in adults with major depressive disorder.

Individuals who have been diagnosed with major depressive disorder and are 18 to 65 years old may be eligible for this study.

For more information on KOASTAL-2, visit our website at: https://www.bcdfoundation.ca/k-opioid-antagonist-mdd-study

Interested in joining the study? If so, please feel free to reach out to us at [email protected]

01/24/2025

KOASTAL-2 is a clinical study taking place in Toronto and Mississauga. This study aims to evaluate the effects of an investigational treatment called Navacaprant on depressive symptoms and anhedonia in adults with major depressive disorder.

Individuals may be eligible for the KOASTAL-2 study if they have been diagnosed with major depressive disorder and are 18 to 65 years old.

To learn more, visit our website at: https://www.bcdfoundation.ca/k-opioid-antagonist-mdd-study

Interested in joining the study? If so, please feel free to reach out to us at [email protected]

01/22/2025

The KOASTAL-2 study taking place in Toronto and Mississauga is assessing a new once-daily treatment called Navacaprant for depressive symptoms and anhedonia (reduced interest or pleasure in most, if not all activities) in adults (18 to 65 years old) with major depressive disorder.

Interested in learning more about the study? Visit: https://www.bcdfoundation.ca/k-opioid-antagonist-mdd-study

Have any questions about the KOASTAL-2 study? If so, please feel free to send us a message here or email us at [email protected]

01/20/2025

A new once-daily treatment called Navacaprant is being evaluated in adults (18 to 65 years old) with major depressive disorder.

For more information, visit our website at: https://www.bcdfoundation.ca/k-opioid-antagonist-mdd-study

Please feel free to message us here or email us at [email protected] if you have any questions!

01/17/2025

The KOASTAL-2 study is evaluating a new once-daily treatment called Navacaprant for depressive symptoms and anhedonia (reduced joy or pleasure in daily activities) in adults (18 to 65 years old) with major depressive disorder.

For more information on the KOASTAL-2 study, visit: https://www.bcdfoundation.ca/k-opioid-antagonist-mdd-study

Have questions? Interested in joining the study? If so, please feel free to message us here or email us at [email protected]

01/08/2025

The Brain and Cognition Discovery Foundation (BCDF) is recruiting participants for KOASTAL-2, a clinical study taking place in Toronto and Mississauga. The KOASTAL-2 study aims to determine if a new treatment called Navacaprant will help alleviate symptoms of depression and anhedonia in adults with major depressive disorder.

To participate or learn more, please reach out to out team at [email protected]

Additionally, for more information on the KOASTAL-2 study, you can visit: https://www.bcdfoundation.ca/k-opioid-antagonist-mdd-study

12/13/2024

The KOASTAL-2 study taking place in Toronto and Mississauga is investigating a new once-daily medicine called Navacaprant for the treatment of depressive symptoms and anhedonia in adults with major depressive disorder.

To learn more about the study, visit: https://www.bcdfoundation.ca/k-opioid-antagonist-mdd-study

If you have any questions, please feel free to send us a message here or by email to [email protected]

12/11/2024

KOASTAL-2 is a clinical study taking place in Toronto/Mississauga, investigating a once-daily medicine called Navacaprant for the treatment of depressive symptoms and anhedonia in adults with major depressive disorder.

Visit our website to learn more about KOASTAL-2: https://www.bcdfoundation.ca/k-opioid-antagonist-mdd-study

For inquiries, please feel free to message us here or email us at [email protected]

12/09/2024

KOASTAL-2 is a clinical study taking place in Toronto/Mississauga that aims to evaluate a once-daily treatment called Navacaprant for adults with major depressive disorder.

To learn more about the KOASTAL-2 study, visit our website at: https://www.bcdfoundation.ca/k-opioid-antagonist-mdd-study

If you have any questions about the study, please message us here or email us at [email protected]

Address

Toronto, ON

Telephone

+16474508045

Website

https://linktr.ee/bcdfoundation

Alerts

Be the first to know and let us send you an email when Brain and Cognition Discovery Foundation - BCDF posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Organization

Send a message to Brain and Cognition Discovery Foundation - BCDF:

Shortcuts

Want your organization to be the top-listed Non Profit Organization in Toronto?